Four-Year Follow-up of the Immunogenicity and Safety of the HPV-16/18 AS04-Adjuvanted Vaccine When Administered to Adolescent Girls Aged 10–14 Years

Four-Year Follow-up of the Immunogenicity and Safety of the HPV-16/18 AS04-Adjuvanted Vaccine When Administered to Adolescent Girls Aged 10–14 Years

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Tino F. Schwarz, Li‐Min Huang, Doris Maribel Rivera Medina, Alejandra Valencia, Tzou‐Yien Lin, Ulrich Behre, Grégory Catteau, Florence Thomas, Dominique Descamps
Format:	Artigo
Sprache:	Englisch
Veröffentlicht:	2012
Online-Zugang:	https://doi.org/10.1016/j.jadohealth.2011.11.004
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years
von: Schwarz, Tino F., et al.
Veröffentlicht: (2019)

A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years
von: Tino F. Schwarz, et al.
Veröffentlicht: (2019)

Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study
von: Romanowski, Barbara, et al.
Veröffentlicht: (2015)

Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study
von: Barbara Romanowski, et al.
Veröffentlicht: (2015)

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule
von: Barbara Romanowski, et al.
Veröffentlicht: (2011)

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: Results from a randomized study
von: Romanowski, Barbara, et al.
Veröffentlicht: (2011)

Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15–55 years
von: Schwarz, Tino F, et al.
Veröffentlicht: (2011)

Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine
von: Paulo Naud, et al.
Veröffentlicht: (2014)

Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination
von: Barbara Romanowski, et al.
Veröffentlicht: (2014)

Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: Results from a randomized study
von: Romanowski, Barbara, et al.
Veröffentlicht: (2014)

Long‐term persistence of systemic and mucosal immune response to HPV‐16/18 AS04‐adjuvanted vaccine in preteen/adolescent girls and young women
von: Tiina Petäjä, et al.
Veröffentlicht: (2010)

Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine
von: Cecília Roteli-Martins, et al.
Veröffentlicht: (2012)

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years: Results from 2 randomized controlled trials
von: Zhu, Fengcai, et al.
Veröffentlicht: (2014)

Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: Final analysis of a long-term follow-up study up to 9.4 years post-vaccination
von: Naud, Paulo S, et al.
Veröffentlicht: (2014)

Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination
von: Hastie, Andrew, et al.
Veröffentlicht: (2020)

Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination
von: Andrew Hastie, et al.
Veröffentlicht: (2020)

Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9–14 Years: A Randomized Trial
von: Huang, Li-Min, et al.
Veröffentlicht: (2017)

Ten‐year immune persistence and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in females vaccinated at 15–55 years of age
von: Schwarz, Tino F., et al.
Veröffentlicht: (2017)

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9–14 years: Results to month 12 from a randomized trial
von: Leung, Ting Fan, et al.
Veröffentlicht: (2015)

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9–14 years: Results to month 12 from a randomized trial
von: Ting Fan Leung, et al.
Veröffentlicht: (2015)

Immunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9–10 year-old girls according to 0–6 month schedule
von: Gilca, Vladimir, et al.
Veröffentlicht: (2014)

Ten‐year immune persistence and safety of the <scp>HPV</scp>‐16/18 <scp>AS</scp>04‐adjuvanted vaccine in females vaccinated at 15–55 years of age
von: Tino F. Schwarz, et al.
Veröffentlicht: (2017)

Immunogenicity of an Oral Polio Vaccine is Unaffected when Co-Administered with a Human Rotavirus Vaccine RIX4414 (Rotarix™) in Latin America
von: Pío López, et al.
Veröffentlicht: (2008)

Safety and Immunogenicity of Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine: A Randomized Trial in 10–25-Year-Old HIV-Seronegative African Girls and Young Women
von: Sow, Papa Salif, et al.
Veröffentlicht: (2013)

Safety and Immunogenicity of Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine: A Randomized Trial in 10–25-Year-Old HIV-Seronegative African Girls and Young Women
von: Papa Salif Sow, et al.
Veröffentlicht: (2012)

Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15–25 years with and without serological evidence of previous exposure to HPV‐16/18
von: Anne Szarewski, et al.
Veröffentlicht: (2011)

Development of an AS04-Adjuvanted HPV Vaccine with the Adjuvant System Approach
von: Nathalie Garçon, et al.
Veröffentlicht: (2011)

Efficacy, immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese women aged 18–25 years: Results from a randomized controlled trial
von: Fengcai Zhu, et al.
Veröffentlicht: (2014)

Vaccination with a Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Cervical Cancer Vaccine in Korean Girls Aged 10-14 Years
von: Kim, Young-Jae, et al.
Veröffentlicht: (2010)

Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18–25 years: Results from a randomized controlled trial
von: Zhu, Feng-Cai, et al.
Veröffentlicht: (2014)

Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years: Follow-up through Month 48 in a Phase III randomized study
von: Einstein, Mark H, et al.
Veröffentlicht: (2014)

Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15–55 years and first-time modelling of antibody responses in mature women: results from an open-label 6–year follow-up study
von: Schwarz, T, et al.
Veröffentlicht: (2015)

Safety and Immunogenicity of a Recombinant Tetravalent Dengue Vaccine in 9–16 Year Olds
von: Luis Villar, et al.
Veröffentlicht: (2013)

Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9–14 Years Versus a 3-Dose Regimen in Women Aged 15–25 Years
von: Puthanakit, Thanyawee, et al.
Veröffentlicht: (2016)

Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9–14 Years Versus a 3-Dose Regimen in Women Aged 15–25 Years
von: Thanyawee Puthanakit, et al.
Veröffentlicht: (2016)

Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: A partially-blind randomised placebo-controlled study
von: Lynette Denny, et al.
Veröffentlicht: (2013)

Immunogenicity and safety of the AS04-HPV-16/18 and HPV-6/11/16/18 human papillomavirus vaccines in asymptomatic young women living with HIV aged 15–25 years: A phase IV randomized comparative study
von: Folschweiller, Nicolas, et al.
Veröffentlicht: (2020)

Immunogenicity and safety of the AS04-HPV-16/18 and HPV-6/11/16/18 human papillomavirus vaccines in asymptomatic young women living with HIV aged 15–25 years: A phase IV randomized comparative study
von: Nicolas Folschweiller, et al.
Veröffentlicht: (2020)

The levels of anti-HPV16/18 and anti-HPV31/33/35/45/52/58 antibodies among AS04-adjuvanted HPV16/18 vaccinated and non-vaccinated Ugandan girls aged 10–16 years
von: Nakalembe, Miriam, et al.
Veröffentlicht: (2014)

Vaccination of boys or catch-up of girls above 11 years of age with the HPV-16/18 AS04-adjuvanted vaccine: where is the greatest benefit for cervical cancer prevention in Italy?
von: Bonanni, Paolo, et al.
Veröffentlicht: (2015)